Eric Singhi/faculty.mdanderson.org
Jul 24, 2025, 18:56
Eric K. Singhi: Is Adjuvant Immunotherapy Needed after Neoadjuvant Chemoimmunotherapy in Early NSCLC?
Eric K. Singhi, Thoracic Medical Oncologist at MD Anderson Cancer Center, shared a poll on X:
“Polling Q6. Early-stage NSCLC.
If a patient with early-stage NSCLC achieves a pCR after neoadjuvant chemoimmunotherapy, is adjuvant immunotherapy still necessary?
- Yes, continue adjuvant IO – 24.6%
- No, pCR means stop – 57.9%
- Depends (comment below) – 17.5%.”
Narjust Florez, Associate Director of the Cancer Care Equity Program and Co-Director Young Lung Cancer Program at Dana-Farber Cancer Institute, shared this post, adding:
“Very controversial question and a gap in lung cancer – what do you think?”
More posts featuring Eric K. Singhi and Narjust Florez.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 24, 2025, 18:44
Jul 24, 2025, 17:45
Jul 24, 2025, 17:32
Jul 24, 2025, 17:24
Jul 24, 2025, 17:20